zeaxanthin and Diabetes-Mellitus--Type-2

zeaxanthin has been researched along with Diabetes-Mellitus--Type-2* in 9 studies

Reviews

2 review(s) available for zeaxanthin and Diabetes-Mellitus--Type-2

ArticleYear
Dietary Intake and Circulating Concentrations of Carotenoids and Risk of Type 2 Diabetes: A Dose-Response Meta-Analysis of Prospective Observational Studies.
    Advances in nutrition (Bethesda, Md.), 2021, 10-01, Volume: 12, Issue:5

    Previous meta-analysis studies have indicated inverse associations between some carotenoids and risks of metabolic syndrome, cardiovascular disease, cancer, and all-cause mortality. However, the results for associations between carotenoids and type 2 diabetes (T2D) remain inconsistent and no systematic assessment has been done on this topic. We conducted a systematic review and meta-analysis to examine the associations of dietary intakes and circulating concentrations of carotenoids with risk of T2D. We searched PubMed and Ovid Embase from database inception to July 2020. Prospective observational studies of carotenoids and T2D risk were included. Random-effects models were used to summarize the RRs and 95% CIs. Thirteen publications were included. Dietary intake of β-carotene was inversely associated with the risk of T2D, and the pooled RR comparing the highest with the lowest categories was 0.78 (95% CI: 0.70, 0.87; I2 = 13.7%; n = 6); inverse associations were also found for total carotenoids (n = 2), α-carotene (n = 4), and lutein/zeaxanthin (n = 4), with pooled RRs ranging from 0.80 to 0.91, whereas no significant associations were observed for β-cryptoxanthin and lycopene. Circulating concentration of β-carotene was associated with a lower risk of T2D, and the pooled RR comparing extreme categories was 0.60 (95% CI: 0.46, 0.78; I2 = 56.2%; n = 7); inverse associations were also found for total carotenoids (n = 3), lycopene (n = 4), and lutein (n = 2), with pooled RRs ranging from 0.63 to 0.85, whereas no significant association was found for circulating concentrations of α-carotene and zeaxanthin when comparing extreme categories. Dose-response analysis indicated that nonlinear relations were observed for circulating concentrations of α-carotene, β-carotene, lutein, and total carotenoids (all P-nonlinearity < 0.05), but not for other carotenoids or dietary exposures. In conclusion, higher dietary intakes and circulating concentrations of total carotenoids, especially β-carotene, were associated with a lower risk of T2D. More studies are needed to confirm the causality and explore the role of foods rich in carotenoids in prevention of T2D. This systematic review was registered at www.crd.york.ac.uk/prospero as CRD42020196616.

    Topics: Carotenoids; Diabetes Mellitus, Type 2; Eating; Humans; Lutein; Observational Studies as Topic; Risk Factors; Zeaxanthins

2021
Mechanism and Potential of Egg Consumption and Egg Bioactive Components on Type-2 Diabetes.
    Nutrients, 2019, Feb-08, Volume: 11, Issue:2

    Type-2 diabetes (T2D) is one of the major global health challenges and a substantial economic burden. Egg and egg-derived components have been indicated to possess antioxidant, anti-inflammatory, anti-hypertensive, immunomodulatory, and anti-cancer activities. However, the scientific evidence about the benefits of egg on T2D is debatable. The relationship between egg consumption and the risk of T2D from observational epidemiological studies is not consistent. Interventional clinical studies, however, provide promising evidence that egg consumption ameliorates the risk of T2D. Current research progress also indicates that some egg components and egg-derived peptides might be beneficial in the context of T2D, in terms of insulin secretion and sensitivity, oxidative stress, and inflammation, suggesting possible application on T2D management. The current review summarizes recent clinical investigations related to the influence of egg consumption on T2D risk and in vivo and in vitro studies on the effect and mechanism of egg components and egg-derived peptides on T2D.

    Topics: Animals; Diabetes Mellitus, Type 2; Diet; Egg Proteins; Eggs; Humans; Lutein; Mice; Rats; Zeaxanthins

2019

Trials

1 trial(s) available for zeaxanthin and Diabetes-Mellitus--Type-2

ArticleYear
Can the Mediterranean diet lower HbA1c in type 2 diabetes? Results from a randomized cross-over study.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2011, Volume: 21, Issue:9

    To investigate the impact of a diet modeled on the traditional Cretan Mediterranean diet on metabolic control and vascular risk in type 2 diabetes.. Twenty-seven subjects (47-77 yrs) with type 2 diabetes were randomly assigned to consume either the intervention diet ad libitum or their usual diet for 12 weeks and then cross over to the alternate diet. Most of the meals and staple foods for the intervention diet were provided. Lipids, glycemic variables, blood pressure, homocysteine, C-reactive protein, plasma carotenoids and body composition (anthropometry and dual energy X-ray absorptiometry) were assessed at baseline, and at the end of both diet periods. Dietary adherence was monitored using plasma carotenoid and fatty acid (FA) analysis, complemented by diet diaries. Compared with usual diet, on the ad libitum Mediterranean intervention diet glycosylated haemoglobin fell from 7.1% (95% CI: 6.5-7.7) to 6.8% (95% CI: 6.3-7.3) (p=0.012) and diet quality improved significantly [plant:animal (g/day) food ratio increased from 1.3 (95% CI: 1.1-1.5) to 5.4 (95% CI: 4.3-6.6) (p<0.001)], plasma lycopene and lutein/zeaxanthin increased (36% and 25%, respectively), plasma saturated and trans FAs decreased, and monounsaturated FAs increased.. A traditional moderate-fat Mediterranean diet improves glycemic control and diet quality in men and women with well-controlled type 2 diabetes, without adverse effects on weight.

    Topics: Absorptiometry, Photon; Aged; Anthropometry; Biomarkers; Blood Glucose; Blood Pressure; Body Composition; C-Reactive Protein; Carotenoids; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet, Mediterranean; Fatty Acids; Female; Glycated Hemoglobin; Homocysteine; Humans; Lipids; Lutein; Lycopene; Male; Middle Aged; Patient Compliance; Surveys and Questionnaires; Xanthophylls; Zeaxanthins

2011

Other Studies

6 other study(ies) available for zeaxanthin and Diabetes-Mellitus--Type-2

ArticleYear
Carotenoid status in type 2 diabetes patients with and without retinopathy.
    Food & function, 2021, May-21, Volume: 12, Issue:10

    Diabetic retinopathy (DR) is one of the leading causes of blindness. Carotenoids are plant-derived pigments required for general health and particularly for vision. In this study, we evaluated the dietary intake and blood carotenoid levels of type 2 diabetes (T2D) patients with and without DR. A cross-sectional case-control study was conducted among 151 age-matched controls and 344 T2D patients, of which 194 had DR and 150 had no DR (NDR). After a complete ophthalmic examination, the demographic, anthropometric and clinical profiles were obtained. Carotenoids in the plasma were measured by HPLC and dietary intakes were obtained using a food frequency questionnaire. The mean plasma levels of carotenoids (except γ-carotene) were significantly lower in the DR group compared to the Control and NDR groups. The dietary intakes of zeaxanthin, lycopene, α-carotene and β-carotene were significantly lower in the NDR group compared to the Control group, and were further lower in the DR group compared to the NDR group. Plasma carotenoid levels were significantly inversely associated with the duration of diabetes, RBS and HbA1c but positively associated with HDL. This study demonstrated decreased plasma levels and lower dietary intakes of carotenoids in DR subjects.

    Topics: beta Carotene; Carotenoids; Case-Control Studies; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Eating; Female; Glycated Hemoglobin; Humans; Lycopene; Male; Middle Aged; Pilot Projects; Retinal Diseases; Surveys and Questionnaires; Zeaxanthins

2021
Dietary intake of carotenoids and risk of type 2 diabetes.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2015, Volume: 25, Issue:4

    Carotenoids may reduce diabetes risk, due to their antioxidant properties. However, the association between dietary carotenoids intake and type 2 diabetes risk is still unclear. Therefore, the objective of this study was to examine whether higher dietary carotenoid intakes associate with reduced type 2 diabetes risk.. Data from 37,846 participants of the European Prospective Investigation into Cancer and Nutrition- Netherlands study were analyzed. Dietary intakes of β-carotene, α-carotene, β-cryptoxanthin, lycopene, lutein & zeaxanthin and the sum of these carotenoids were assessed using a validated food frequency questionnaire. Incident type 2 diabetes was mainly self-reported, and verified against general practitioner information. Mean ±SD total carotenoid intake was 10 ± 4 mg/day. During a mean ±SD follow-up of 10 ± 2 years, 915 incident cases of type 2 diabetes were ascertained. After adjustment for age, sex, diabetes risk factors, dietary intake, waist circumference and BMI, higher β-carotene intakes associated inversely with diabetes risk [Hazard Ratio quartile 4 versus quartile 1 (HR(Q4)): 0.78 (95%CI:0.64,0.95), P-linear trend 0.01]. For α-carotene, a borderline significant reduced risk was observed, with a HR(Q4) of 0.85 (95%CI:0.70,1.03), and P-linear trend 0.05. β-cryptoxanthin, lycopene, lutein & zeaxanthin, and the sum of all carotenoids did not associate with diabetes risk.. This study shows that diets high in β-carotene and α-carotene are associated with reduced type 2 diabetes in generally healthy men and women.

    Topics: Aged; Antioxidants; beta Carotene; Carotenoids; Cryptoxanthins; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Follow-Up Studies; Humans; Incidence; Lutein; Lycopene; Male; Middle Aged; Netherlands; Nutrition Assessment; Prospective Studies; Risk Factors; Surveys and Questionnaires; Zeaxanthins

2015
MACULAR PIGMENT OPTICAL DENSITY IS LOWER IN TYPE 2 DIABETES, COMPARED WITH TYPE 1 DIABETES AND NORMAL CONTROLS.
    Retina (Philadelphia, Pa.), 2015, Volume: 35, Issue:9

    This study was designed to investigate the optical density of macular pigment in Type 1 and Type 2 diabetes subjects relative to normal controls.. One hundred and fifty subjects were recruited to the study and divided into one of the three study groups on the basis of their health status, as follows: Group 1: Healthy controls; Group 2: Type 1 diabetes; Group 3: Type 2 diabetes. Macular Pigment Optical Density, at 0.5° of retinal eccentricity, was measured using customized heterochromatic flicker photometry. Dietary intake of macular carotenoids was quantified using a lutein and zeaxanthin food frequency questionnaire. Diabetes type, duration, medication, smoking habits, glycosylated hemoglobin (HbA1C), and serum lipid levels were recorded, whereas visual acuity, body mass index, and diabetic retinopathy grade were measured for each participant.. One-way analysis of variance revealed a statistically significant difference in body mass index, age, high-density lipoprotein cholesterol and HbA1C between the three groups (P < 0.01 for all). Chi-square analysis revealed a statistically significant difference in diabetic retinopathy distribution (P < 0.01). None of these variables exhibited a statistically significant correlation with macular pigment optical density for any study group (P > 0.05 for all). There was no difference in dietary carotenoid intake between groups. Macular pigment optical density was lower among Type 2 diabetes subjects (0.33 ± 0.21) compared with Type 1 diabetes (0.49 ± 0.23) and controls (0.48 ± 0.35). General linear model analysis, including age, body mass index, diabetes duration, diabetic retinopathy status, high-density lipoprotein cholesterol, and HbA1C as covariates, revealed a statistically significant effect of diabetes type on macular pigment optical density (F = 2.62; P = 0.04).. Macular pigment optical density was statistically significantly lower in Type 2 diabetes compared with Type 1 diabetes and normal controls. Although body mass index was higher in the Type 2 diabetes group, the lower macular pigment optical density levels observed among Type 2 diabetes seem not to be attributable to differences in dietary carotenoid intake or to the specific presence of diabetes, diabetic control, duration, or diabetic retinopathy.

    Topics: Adult; Aged; Body Mass Index; Case-Control Studies; Cross-Sectional Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diet; Feeding Behavior; Female; Glycated Hemoglobin; Healthy Volunteers; Humans; Lipids; Lutein; Macular Pigment; Male; Middle Aged; Photometry; Visual Acuity; Zeaxanthins

2015
Macular pigment optical density measured by dual-wavelength autofluorescence imaging in diabetic and nondiabetic patients: a comparative study.
    Investigative ophthalmology & visual science, 2010, Volume: 51, Issue:11

    To compare macular pigment optical density (MPOD) in type 2 diabetic and nondiabetic patients by using dual-wavelength autofluorescence imaging and to investigate the correlation of MPOD with glycosylated hemoglobin (HbA1C) and serum lipid levels.. Forty-three patients were divided into groups 1 (controls, n = 14), 2 (diabetic without retinopathy, n = 17), and 3 (diabetic with mild nonproliferative retinopathy, n = 12). MPOD was measured with a modified confocal scanning laser ophthalmoscope and compared among groups (analysis of variance). The correlation of HbA1C and serum lipid (HDL, LDL, total cholesterol, and triglycerides) levels with MPOD was determined for each group (linear regression analysis).. Mean ± SD ages in groups 1 (56.2 ± 11.7 years), 2 (58.6 ± 11.5 years), and 3 (62.8 ± 9.8 years) were similar (P = 0.324). Mean MPOD averaged in a 2°-diameter circle around the fovea was significantly different between the three groups: 1, (0.29 ± 0.07 density units [DU]), 2 (0.22 ± 0.09 DU), and 3 (0.14 ± 0.05 DU) (P < 0.001). There was a significant difference in mean MPOD levels at 0.5° between groups 1 (0.51 ± 0.12 DU) and 2 (0.24 ± 0.11 DU; P < 0.001), but not between groups 2 and 3 (0.33 ± 0.15 DU; P > 0.05). A significant inverse correlation was observed between HbA1C levels and mean MPOD, averaged at 2° around the fovea in all patients (r = -0.63, P < 0.001). No significant correlations were found between MPOD and serum lipid levels or age.. Type 2 diabetic patients, with or without retinopathy, had reduced MPOD when compared with that in nondiabetic patients. In addition, a significant inverse correlation between MPOD and HbA1C levels was observed.

    Topics: Densitometry; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fluorescein Angiography; Glycated Hemoglobin; Humans; Image Enhancement; Lipids; Lutein; Male; Middle Aged; Ophthalmoscopy; Prospective Studies; Retina; Retinal Pigments; Xanthophylls; Zeaxanthins

2010
Plasma carotenoids and diabetic retinopathy.
    The British journal of nutrition, 2009, Volume: 101, Issue:2

    Diabetic retinopathy increases with duration of diabetes and may be associated with carotenoid status. Carotenoids alter the pro-oxidation/antioxidation balance, and circulating levels depend largely on dietary intake. Lower levels have been reported in diabetes and age-related macular degeneration; however, little is known of the relationship between carotenoids and diabetic complications. Consequently, the purpose of the present study was to evaluate the relationship between plasma carotenoids and diabetic retinopathy. We assessed the carotenoid-retinopathy relationship in 111 individuals with type 2 diabetes in a community-based, cross-sectional study. We photodocumented retinal status and used HPLC to measure plasma carotenoid concentrations. Data for clinical and demographic variables and risk factors for diabetic retinopathy were obtained from 24 h urine and fasting blood samples, and an interviewer-assisted lifestyle questionnaire. We found that the combined lycopene and lutein/zeaxanthin (non-pro-vitamin A (non-PVA) carotenoid) concentration when compared with the pro-vitamin A (PVA) carotenoids (alpha-carotene, beta-carotene and beta-cryptoxanthin) was significantly lower in the retinopathy than non-retinopathy group (OR 1.2 (95% CI 1.0, 1.4) v. 1.6 (95% CI 1.4, 1.7), respectively; P=0.009). A higher non-PVA:PVA ratio also predicted a lower risk of diabetic retinopathy, after adjustment for potential confounders (OR 0.33 (95% CI 0.12, 0.95); P=0.039). Finally, a higher concentration of PVA carotenoids was associated with greater odds of diabetic retinopathy, after adjustment for risk factors (P=0.049). We suggest synergies between carotenoids are implicated in diabetic retinopathy, independent of established risk factors. Importantly, our observations indicate dietary modulation of retinopathy risk may be possible by increasing intakes of lutein- and lycopene-rich foods.

    Topics: Adult; Aged; Antioxidants; beta Carotene; Biomarkers; Blood Glucose; Carotenoids; Chi-Square Distribution; Cross-Sectional Studies; Cryptoxanthins; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Humans; Lutein; Lycopene; Male; Middle Aged; Risk; Xanthophylls; Zeaxanthins

2009
Plasma lycopene, other carotenoids, and the risk of type 2 diabetes in women.
    American journal of epidemiology, 2006, Sep-15, Volume: 164, Issue:6

    The authors conducted a nested case-control study from 1992 to 2003 among US women aged 45 years or older and free from cardiovascular disease and cancer to examine the prospective association among plasma lycopene, other carotenoids, and the risk of developing type 2 diabetes. During 10 years of follow-up, 470 cases of incident type 2 diabetes were selected and individually matched on age (+/- 1 year) and follow-up time to 470 nondiabetic controls. Baseline plasma levels of lycopene, alpha-carotene, beta-carotene, beta-cryptoxanthin, and lutein/zeaxanthin were similar in cases and controls (all p > 0.05). A possible crude inverse association between plasma lycopene and risk of type 2 diabetes was attenuated upon multivariate adjustment. After control for plasma total cholesterol and known diabetes risk factors, the multivariate odds ratios of type 2 diabetes in the highest versus the lowest quartile of plasma carotenoids were 1.13 (95% confidence interval (CI): 0.60, 2.13) for lycopene, 1.27 (95% CI: 0.63, 2.57) for alpha-carotene, 1.10 (95% CI: 0.57, 2.13) for beta-carotene, 0.91 (95% CI: 0.46, 1.81) for beta-cryptoxanthin, and 1.35 (95% CI: 0.68, 2.69) for lutein/zeaxanthin. There was no prospective association between baseline plasma carotenoids and the risk of type 2 diabetes in middle-aged and older women.

    Topics: Aged; Aspirin; beta Carotene; Carotenoids; Case-Control Studies; Cryptoxanthins; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Incidence; Logistic Models; Lutein; Lycopene; Middle Aged; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Surveys and Questionnaires; United States; Xanthophylls; Zeaxanthins

2006